Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Conditions:   Allergic Rhinitis;   Conjunctivitis Interventions:   Drug: REGN5713;   Drug: REGN5714;   Drug: REGN5715;   Other: Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials